Stay updated with breaking news from Nasdaq Fold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, August 8th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link. Amicus Therapeutics […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Research analysts at Cantor Fitzgerald boosted their FY2023 EPS estimates for Amicus Therapeutics in a research note issued to investors on Wednesday, July 19th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of ($0.59) per share for the year, up from […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 21,540,000 shares, an increase of 10.0% from the June 15th total of 19,580,000 shares. Based on an average daily volume of 2,470,000 shares, […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO Bradley L. Campbell sold 11,700 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $11.36, for a total value of $132,912.00. Following the transaction, the chief executive officer now owns 823,454 shares in the […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) Chairman John F. Crowley sold 6,044 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $11.36, for a total transaction of $68,659.84. Following the completion of the transaction, the chairman now owns 956,317 shares in the […]